NDASUBCUTANEOUSSOLUTION
Approved
Oct 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VYALEV (foscarbidopa/foslevodopa) is a subcutaneous solution combining two prodrugs that are converted to carbidopa and levodopa in the body, approved in October 2024 for Parkinson's disease management. This formulation enables continuous subcutaneous delivery, bypassing gastrointestinal absorption variability. The mechanism leverages dopamine replacement via levodopa with decarboxylase inhibition to reduce peripheral conversion and optimize central nervous system availability.
Growth13.6 years to LOE
Early-stage growth product with minimal competitive pressure; commercial teams will focus on market education, payer access, and patient enrollment in a newly approved category.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VYALEV represents a high-visibility launch opportunity in a franchise with significant unmet need; roles on this brand will center on market education, establishing payer coverage, and building a patient base in a novel delivery category. Career growth potential is substantial given 13+ years of patent protection and AbbVie's established Parkinson's franchise infrastructure.
Brand Manager
Worked on VYALEV at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.